Device clinical trial database
This article was originally published in The Gray Sheet
Executive Summary
Health Industry Manufacturers Association requests in a July 14 letter to FDA a 30-day extension of the comment period pertaining to the agency's June 22 notice seeking input on the feasibility of including medical device clinical trials in a public data bank. FDA held a public meeting July 8 to gather input on the issue (1"The Gray Sheet" July 12, p. 27). Because the agency is required by the FDA Modernization Act to submit a recommendation to Congress on the subject by Nov. 21, FDA may hesitate to extend the current Aug. 23 deadline
You may also be interested in...
Public Device Trial Database Raises Confidentiality Concerns - Industry Reps
Inclusion of device clinical trial information in a mandatory, public database could stifle technological innovation in the device industry, trade association reps cautioned at a July 8 public meeting sponsored by FDA.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.